American Journal of Obstetrics & Gynecology
Volume 199, Issue 5 , Pages 539.e1-539.e6, November 2008

Influence of race on tolerance of platinum-based chemotherapy and clinical outcomes in women with advanced and recurrent cervical cancer: a pooled analysis of 3 Gynecologic Oncology Group studies

  • Steven C. Plaxe, MD

      Affiliations

    • Division of Gynecologic Oncology, University of California, San Diego, San Diego, CA
    • ,
  • Sandra E. Brooks, MD

      Affiliations

    • Division of Cancer Prevention and Gynecologic Oncology, Norton Cancer Institute Louisville, KY
    • ,
  • Chunquiao Tian, MS

      Affiliations

    • Gynecologic Oncology Group Statistical and Data Center, Buffalo, NY
    • Corresponding Author InformationReprints: Ms Denise Mackey, GOG, Administrative Office, Four Penn Center, 1600 JKF Blvd, Suite 1020, Philadelphia, PA 19102
    • ,
  • Jeffrey D. Bloss, MD

      Affiliations

    • Genetech, Inc, South San Francisco, CA
    • ,
  • David H. Moore, MD

      Affiliations

    • Gynecologic Oncology of Indiana, Indianapolis, IN
    • ,
  • Harry J. Long, MD

      Affiliations

    • Department of Medical Oncology, Mayo Clinic, Rochester, MN

Received 21 September 2007; received in revised form 28 January 2008; accepted 17 April 2008. published online 20 June 2008.

Objective

This study was undertaken to compare toxicity and outcomes from cisplatin-based combination chemotherapy for black and white women with advanced /recurrent cervical cancer.

Study Design

Frequencies of grade 3 and 4 toxicities, response, and survival were compared by race using data from 3 Gynecologic Oncology Group studies.

Results

Black women experienced significantly less grade 3 and 4 neutropenia (63% vs 82%), leukopenia (58% vs 79%), thrombocytopenia (10% vs 23%), and adverse events of any nature (84% vs 93%) compared with white women. Black patients were not at increased risk of disease progression (adjusted relative risk, 1.11; 95% confidence interval, 0.88-1.38; P = .382) or death (adjusted relative risk, 1.02; 95% confidence interval, 0.82-1.26; P = .893).

Conclusion

Cisplatin-based chemotherapy delivered in a protocol setting for advanced/recurrent carcinoma of the cervix appears better tolerated by black women.

Key words: cervical cancer, chemotherapy, race

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 30.00 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

 This study was supported by National Cancer Institute grants to the Gynecologic Oncology Group Administrative Office (CA 27469) and the Gynecologic Oncology Group Statistical and Data Center (CA 37517).

 Cite this article as: Plaxe SC, Brooks SE, Tian C, et al. Influence of race on tolerance of platinum-based chemotherapy and clinical outcomes in women with advanced and recurrent cervical cancer: a pooled analysis of 3 Gynecologic Oncology Group studies. Am J Obstet Gynecol 2008;199:539.e1-539.e6.

PII: S0002-9378(08)00434-1

doi:10.1016/j.ajog.2008.04.038

American Journal of Obstetrics & Gynecology
Volume 199, Issue 5 , Pages 539.e1-539.e6, November 2008

Article Tools

* Image Usage & Resolution